A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway

Journal of Biomolecular Screening

Volumn 21, Issue 6, 2016, Pages 626-633

  Voter, Andrew F ^a   Manthei, Kelly A ^b   Keck, James L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

DNA repair; Fanconi anemia; protein interaction inhibitor screen

Indexed keywords

ANTINEOPLASTIC AGENT; FANCONI ANEMIA GROUP M PROTEIN; NUCLEAR PROTEIN; PEPTIDES AND PROTEINS; PHOSPHOPROTEIN; PROTEIN INHIBITOR; PROTEIN PROTEIN INTERACTION INHIBITOR; RECQ MEDIATED GENOME INSTABILITY PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN; UNCLASSIFIED DRUG; DNA HELICASE; FANCM PROTEIN, HUMAN; MULTIPROTEIN COMPLEX; RECQ HELICASE;

ARTICLE; BINDING SITE; CANCER RESISTANCE; COMPLEX FORMATION; DNA CROSS LINKING; DNA REPAIR; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG SENSITIZATION; FANCONI ANEMIA; FLUORESCENCE POLARIZATION; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; IC50; ISOTHERMAL TITRATION CALORIMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SURFACE PLASMON RESONANCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DNA DAMAGE; DRUG EFFECTS; DRUG SCREENING; GENETICS; HUMAN; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA HELICASES; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; FANCONI ANEMIA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MULTIPROTEIN COMPLEXES; PROTEIN INTERACTION MAPS; RECQ HELICASES;

EID: 84975879845     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057116635503     Document Type: Article

References (25)

1. Hanahan D., Weinberg R. A., Hallmarks of Cancer: The Next Generation. Cell 2011, 144, 646-674.
2. Bouwman P., Jonkers J., The Effects of Deregulated DNA Damage Signalling on Cancer Chemotherapy Response and Resistance. Nat. Rev. Cancer 2012, 12, 587-598.
3. Schmoll H.-J., Jordan K., Huddart R., et al., on behalf of the ESMO Guidelines Working Group. Testicular Seminoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2010, 21 (Suppl. 5), v140-v146.
4. D'Addario G., Fruh M., Reck M., et al., on behalf of the ESMO Guidelines Working Group. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2010, 21 (Suppl. 5), v116-v119.
5. Oza A. M., Cook A. D., Pfisterer J., et al. Standard Chemotherapy with or without Bevacizumab for Women with Newly Diagnosed Ovarian Cancer (ICON7): Overall Survival Results of a Phase 3 Randomised Trial. Lancet Oncol. 2015, 16, 928-936.
6. Deans A. J., West S. C., DNA Interstrand Crosslink Repair and Cancer. Nat. Rev. Cancer 2011, 11, 467-480.
7. Mouw K. W., D'Andrea A. D., Crosstalk between the Nucleotide Excision Repair and Fanconi Anemia/BRCA Pathways. DNA Repair 2014, 19, 130-134.
8. Chen Q., The FA/BRCA Pathway Is Involved in Melphalan-Induced DNA Interstrand Cross-Link Repair and Accounts for Melphalan Resistance in Multiple Myeloma Cells. Blood 2005, 106, 698-705.
9. Yao C., Du W., Chen H., et al. The Fanconi Anemia/BRCA Pathway Is Involved in DNA Interstrand Cross-Link Repair of Adriamycin-Resistant Leukemia Cells. Leuk. Lymphoma 2015, 56, 755-762.
10. Chen C. C., Taniguchi T., D'Andrea A., The Fanconi Anemia (FA) Pathway Confers Glioma Resistance to DNA Alkylating Agents. J. Mol. Med. 2007, 85, 497-509.
11. Burkitt K., Ljungman M., Phenylbutyrate Interferes with the Fanconi Anemia and BRCA Pathway and Sensitizes Head and Neck Cancer Cells to Cisplatin. Mol. Cancer 2008, 7, 24.
12. Toshiyasu T, Tischkowitz M., Ameziane N., et al. Disruption of the Fanconi Anemia-BRCA Pathway in Cisplatin-Sensitive Ovarian Tumors. Nat. Med. 2003, 9, 568-574.
13. Patch A.-M., Christie E. L., Etemadmoghadam D., et al. Whole-Genome Characterization of Chemoresistant Ovarian Cancer. Nature 2015, 521, 489-494.
14. Chirnomas D., Chemosensitization to Cisplatin by Inhibitors of the Fanconi Anemia/BRCA Pathway. Mol. Cancer Ther. 2006, 5, 952-961.
15. Räschle M., Knipscheer P., Enoiu M., et al. Mechanism of Replication-Coupled DNA Interstrand Crosslink Repair. Cell 2008, 134, 969-980.
16. Zhang J., Dewar J. M., Budzowska M., et al. DNA Interstrand Cross-Link Repair Requires Replication-Fork Convergence. Nat. Struct. Mol. Biol. 2015, 22, 242-247.
17. Deans A. J., West S. C., FANCM Connects the Genome Instability Disorders Bloom's Syndrome and Fanconi Anemia. Mol. Cell 2009, 36, 943-953.
18. Seki M., Nakagawa T., Seki T., et al. Bloom Helicase and DNA Topoisomerase III Are Involved in the Dissolution of Sister Chromatids. Mol. Cell. Biol. 2006, 26, 6299-6307.
19. Singh T. R., Ali A. M., Busygina V., et al. BLAP18/RMI2, a Novel OB-Fold-Containing Protein, Is an Essential Component of the Bloom Helicase-Double Holliday Junction Dissolvasome. Genes Dev. 2008, 22, 2856-2868.
20. Manthei K. A., Keck J. L., The BLM Dissolvasome in DNA Replication and Repair. Cell. Mol. Life Sci. 2013, 70, 4067-4084.
21. Hoadley K. A., Xue Y., Ling C., et al. Defining the Molecular Interface That Connects the Fanconi Anemia Protein FANCM to the Bloom Syndrome Dissolvasome. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 4437-4442.
22. Hoadley K. A., Xu D., Xue Y., et al. Structure and Cellular Roles of the RMI Core Complex from the Bloom Syndrome Dissolvasome. Structure 2010, 18, 1149-1158.
23. Lopper M., Boonsombat R., Sandler S. J., et al. A Hand-Off Mechanism for Primosome Assembly in Replication Restart. Mol. Cell 2007, 26, 781-793.
24. Zhang J.-H., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
25. Navratilova I., Hopkins A. L., Fragment Screening by Surface Plasmon Resonance. ACS Med. Chem. Lett. 2010, 1, 44-48.